Health Canada has begun a new consultation on proposed revisions to the Cosmetic Ingredient Hotlist, opening the door to significant changes in how cosmetic ingredients are reviewed, classified, and permitted for use in Canada. The consultation period runs from November 19th, 2025, to February 17th, 2026, marking a critical window for industry to review the proposed conditions, assess formulas, and submit evidence-backed feedback.
The Hotlist is one of the primary tools Health Canada uses to communicate ingredient safety expectations. Any updates to this list can directly influence formulation decisions, ingredient sourcing, product classification, and regulatory compliance under the Food and Drugs Act and the Cosmetic Regulations. For businesses operating in the beauty and personal care space, understanding and preparing for the proposed changes is essential.
- Understanding the Role of the Cosmetic Ingredient Hotlist in Canada
- Overview of Health Canada’s Proposed Hotlist Additions
- Proposed Restrictions for Basic Violet 4
- Proposed Restrictions for Basic Blue 7
- Proposed Restrictions for Polyaminopropyl Biguanide (PHMB)
- Updated Prohibition for Symphytum Species
- Brucine and Its Salts Proposed as Prohibited
- Removal of the Standalone Entry for Imperatorin
- Revised Restrictions for Furocoumarins
- Other Technical Revisions and Synonym Updates
- How to Participate in the Hotlist Consultation
- Preparing Your Cosmetic Brand for Regulatory Changes in Canada
- Staying Informed About Canadian Cosmetic Regulations and Safety Standards
- FAQ
Understanding the Role of the Cosmetic Ingredient Hotlist in Canada
The Cosmetic Ingredient Hotlist is a key reference document published by Health Canada to help manufacturers, importers, and brand owners understand which substances may pose safety concerns when used in cosmetic products. It is not a regulation on its own, but it directly supports compliance with the Food and Drugs Act and the Cosmetic Regulations. When an ingredient appears on the Hotlist, it means Health Canada has reviewed available scientific evidence and determined that the ingredient either cannot be used safely in cosmetics or can only be used under specific conditions.
How the Hotlist Supports Compliance
The Hotlist is used as an advisory tool to help companies determine whether a cosmetic may contravene section 16 of the Food and Drugs Act, which prohibits the sale of any cosmetic that may cause injury. It also helps clarify when an ingredient’s properties may push a product outside the cosmetic category altogether. For example, an ingredient with therapeutic effects could shift a product into drug or natural health product status, even if it is marketed as a cosmetic. The Hotlist helps prevent these misclassifications by outlining known risk factors and setting clear limits for certain substances.
What It Means When an Ingredient Appears on the Hotlist
When Health Canada places an ingredient on the Hotlist, it signals that the substance has been linked to health risks such as toxicity, sensitization, carcinogenicity, or inappropriate use conditions. An ingredient may be identified as prohibited, meaning it cannot be used in any cosmetic, or restricted, meaning it can only be used at specified concentrations, in certain product formats, or with mandatory cautionary statements. The presence of an ingredient on the Hotlist does not automatically ban a product, but it requires companies to follow the listed conditions to remain compliant.
Why the Hotlist Is Not Exhaustive
Although the Hotlist is an important compliance tool, it is not a complete inventory of every substance that may pose a safety concern. Companies remain responsible for ensuring product safety even if an ingredient does not appear on the list. This means they must stop selling cosmetics immediately if new data suggests that an ingredient could cause harm, regardless of the Hotlist’s publication cycle. In practice, the Hotlist acts as a guide, but it does not replace the broader legal obligation placed on cosmetic companies to ensure consumer safety.
How Health Canada Updates the Hotlist
Health Canada updates the Hotlist on a periodic, as-needed basis. Proposed changes are informed by a wide body of evidence, including peer-reviewed scientific journals, international regulatory decisions, toxicology reports, and assessments conducted under the Canadian Environmental Protection Act, 1999 (CEPA). These updates ensure that the Hotlist reflects current scientific knowledge rather than historical assumptions. The most recent update prior to the current consultation occurred in August 2025, and the new proposals reflect emerging data, evolving exposure patterns, and updated expert evaluations.
Overview of Health Canada’s Proposed Hotlist Additions
Several new substances have been proposed for inclusion in the restricted category. These additions stem from Chemicals Management Plan (CMP) assessments and updated exposure data submitted through cosmetic notifications.
Proposed Restrictions for Basic Violet 4
Health Canada is proposing to add Basic Violet 4 as a restricted ingredient due to potential carcinogenicity. Earlier assessments concluded the risk to human health was low at the time, but recent cosmetic notification data indicates that exposure levels have increased. Under the proposal, Basic Violet 4 would not be permitted in leave-on hair products, while limited concentrations would be allowed in hair dyes and rinse-off formulations. These limits reflect updated exposure modelling and the need to mitigate potential risks.
Proposed Restrictions for Basic Blue 7
Basic Blue 7 is also being proposed for addition as a restricted ingredient for similar reasons. Although previous evaluations found the risk low, newer data confirms that consumer exposure has risen. The proposed conditions prohibit its use in leave-on hair products and establish concentration limits for hair dyes, rinse-off hair care, nail products, bath products, and other cosmetic formats. This change underscores Health Canada’s commitment to reassessing ingredient safety as market use evolves.
Proposed Restrictions for Polyaminopropyl Biguanide (PHMB)
Polyaminopropyl Biguanide, commonly known as PHMB, is being proposed for restricted use due to concerns involving inhalation exposure and skin sensitization. The proposal would prohibit PHMB in spray or aerosol products because fine mists may impair lung function. For topically applied products that do not produce aerosols, Health Canada is proposing a maximum concentration limit that would allow controlled use while minimizing sensitization risks. This aligns Canada’s approach with emerging international perspectives on PHMB.
Key Revisions to Existing Ingredient Entries
In addition to new substances, the consultation includes several revisions to existing Hotlist entries. These changes reflect updated toxicology data, new evidence on exposure, and a need for clearer regulatory expectations.
Updated Prohibition for Symphytum Species
Health Canada is proposing to remove the previous exception for Symphytum officinale within the broader entry for Symphytum species (commonly known as comfrey). Although earlier studies suggested this species did not contain certain harmful alkaloids, recent evidence confirms the presence of echimidine and other carcinogenic pyrrolizidine alkaloids. As a result, Symphytum officinale would now be captured fully under the prohibited entry for all Symphytum species.
Brucine and Its Salts Proposed as Prohibited
Brucine is currently restricted on the Hotlist, but Health Canada is proposing to reclassify it as prohibited due to its significant acute toxicity, neurotoxic properties, and ability to be absorbed through the skin. The proposal also expands the entry to include brucine salts such as brucine sulfate, since the toxicological behaviour of these salts is expected to mirror the parent compound. Limited safety data and the possibility of long-term harm further support this reclassification.
Removal of the Standalone Entry for Imperatorin
Imperatorin, currently listed as a prohibited ingredient, is being proposed for removal as a standalone entry. Instead, it would be incorporated as a synonym within the broader entry for furocoumarins. This reflects Health Canada’s assessment that Imperatorin presents similar risks to other furocoumarins, particularly phototoxicity and photomutagenicity, and does not require a separate listing.
Revised Restrictions for Furocoumarins
Furocoumarins have long been associated with phototoxic and photocarcinogenic reactions, particularly in conjunction with UVA exposure. Health Canada is proposing to clarify that these substances cannot be intentionally added to cosmetics and may only be present at trace levels when they occur naturally in plant extracts. The proposal also extends the maximum permitted concentration to all leave-on products, acknowledging that consumers may be exposed to sunlight after applying any leave-on cosmetic, not only sun-tanning preparations.
Other Technical Revisions and Synonym Updates
Health Canada is also proposing several minor corrections, updated Chemical Abstracts Service (CAS) numbers, and new synonyms across multiple entries. These updates are intended to improve clarity and help industry correctly identify regulated substances without ambiguity.
How to Participate in the Hotlist Consultation
Industry stakeholders, including cosmetic manufacturers, formulators, ingredient suppliers, importers, brand owners, and professional associations, are encouraged to review the proposed updates and provide feedback. Health Canada welcomes evidence-supported submissions, which can be sent by email to cosmetics@hc-sc.gc.ca or mailed to the Cosmetics Program at the Consumer and Hazardous Products Safety Directorate in Ottawa.
All comments received by February 17th, 2026, will be reviewed, and Health Canada will publish a summary of responses. Notifications will also be sent to subscribers of the cosmetics mailing list and individuals who have previously submitted a cosmetic notification form.
Preparing Your Cosmetic Brand for Regulatory Changes in Canada
The proposed updates to the Cosmetic Ingredient Hotlist reinforce the need for brands to regularly audit their ingredient portfolios and confirm that all formulas continue to meet safety expectations. As scientific evidence evolves and exposure patterns shift, regulatory requirements may change accordingly.
Companies can begin preparing by reviewing the proposed entries, identifying ingredients that may require reformulation, and contacting suppliers for updated documentation. Early planning helps prevent market disruptions and ensures that products remain compliant as Canada continues to refine its cosmetic regulatory framework.
Staying Informed About Canadian Cosmetic Regulations and Safety Standards
Health Canada’s consultation reflects the department’s commitment to maintaining a modern, evidence-based approach to cosmetic safety. Brands that stay informed, participate in consultations, and proactively evaluate ingredient safety will be well positioned to navigate the next phase of regulatory updates in Canada.
Your Partner in Global Cosmetic Regulatory Compliance
If your team is preparing for the upcoming Hotlist changes or needs clarity on how these updates may influence your ingredient choices and product roadmap, Source Nutraceutical Inc. (SNI) is ready to guide you.
Our regulatory specialists support brands across Canada, the United States, and Europe with formulation assessments, reformulation strategies, cross-border labelling compliance, and long-term regulatory planning. Connect with us today to ensure your cosmetic products remain competitive, compliant, and positioned for success in every market you serve.
💄 More about our services here.
💡 Compliance is easy with the right support!
📩 info@sourcenutra.com
⬇️ Send us a request for support or an introductory call
FAQ
What is the Cosmetic Ingredient Hotlist?
The Hotlist is a Health Canada advisory document that identifies cosmetic ingredients that are prohibited or restricted due to safety concerns. It helps brands understand which substances may cause a product to violate the Food and Drugs Act or the Cosmetic Regulations.
Does the Hotlist have legal authority?
Although the Hotlist itself is not a regulation, failing to meet its conditions can result in a product contravening section 16 of the Food and Drugs Act. This can trigger compliance actions such as recalls or stop-sales.
Why does an ingredient appear on the Hotlist?
An ingredient is added when scientific evidence shows it may pose health risks at certain concentrations or under specific conditions. Health Canada reviews global research, toxicology data, and international regulatory decisions when making this determination.
How often is the Hotlist updated?
Health Canada updates the Hotlist when new evidence emerges or when ingredient use patterns change. These updates do not follow a fixed schedule and are based on weight of evidence.
What should companies do when proposed Hotlist updates are released?
Companies should review affected ingredients, evaluate formulas, and reach out to suppliers for updated documentation. Early action helps ensure continued compliance once final changes are published.
✷ The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.
